Jill Jene
Directeur/Membre du Conseil chez LIPOCINE INC.
Fortune : - $ au 30/04/2024
Postes actifs de Jill Jene
Sociétés | Poste | Début | Fin |
---|---|---|---|
LIPOCINE INC. | Directeur/Membre du Conseil | 11/04/2022 | - |
Independent Dir/Board Member | 11/04/2022 | - |
Historique de carrière de Jill Jene
Anciens postes connus de Jill Jene
Sociétés | Poste | Début | Fin |
---|---|---|---|
ADAMAS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2020 | 24/11/2021 |
PDL BIOPHARMA, INC. | Corporate Officer/Principal | 21/05/2018 | 15/08/2020 |
Aria Pharmaceuticals, Inc.
Aria Pharmaceuticals, Inc. Drugstore ChainsRetail Trade twoXAR, Inc. provides drug discovery services. Its DUMA platform rapidly evaluates massive public and proprietary datasets to identify and rank probability drug-disease matches. The company was founded by Andrew A. Radin and Andrew M. Radin in 2014 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 01/05/2017 | 01/05/2018 |
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Corporate Officer/Principal | 01/04/2006 | 01/05/2017 |
Formation de Jill Jene
Northwestern University | Doctorate Degree |
DePaul University | Masters Business Admin |
Bradley University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Opérationnelle
Corporate Officer/Principal | 4 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 4 |
Retail Trade | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
LIPOCINE INC. | Health Technology |
Entreprise privées | 4 |
---|---|
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Aria Pharmaceuticals, Inc.
Aria Pharmaceuticals, Inc. Drugstore ChainsRetail Trade twoXAR, Inc. provides drug discovery services. Its DUMA platform rapidly evaluates massive public and proprietary datasets to identify and rank probability drug-disease matches. The company was founded by Andrew A. Radin and Andrew M. Radin in 2014 and is headquartered in Palo Alto, CA. | Retail Trade |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |